Skip to content

Replimune Group REPL Other Non-Current Assets

Other Non-Current Assets at other companies

Amgen logo
AmgenAMGN
$12.76B+12.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$4.38M-35.6%
Immunome logo
ImmunomeIMNM
$5.36M+23.4%
CG Oncology logo
CG OncologyCGON
$2.68M-89.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$1.45M-44.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$61M-14.1%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's other non-current assets?
Replimune Group (REPL) reported other non-current assets of $1.2M in Q4 2025.
How has Replimune Group's other non-current assets changed year-over-year?
Replimune Group's other non-current assets decreased by 0.0% year-over-year, from $1.2M to $1.2M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.